company background image

Caregen KOSDAQ:A214370 Stock Report

Last Price


Market Cap







10 May, 2022


Company Financials
A214370 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health6/6

A214370 Stock Overview

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Caregen
Historical stock prices
Current Share Price₩105,200.00
52 Week High₩133,000.00
52 Week Low₩50,400.00
1 Month Change-6.82%
3 Month Change69.95%
1 Year Change66.46%
3 Year Changen/a
5 Year Change53.35%
Change since IPO-1.68%

Recent News & Updates

Shareholder Returns

A214370KR PharmaceuticalsKR Market

Return vs Industry: A214370 exceeded the KR Pharmaceuticals industry which returned -26.1% over the past year.

Return vs Market: A214370 exceeded the KR Market which returned -17% over the past year.

Price Volatility

Is A214370's price volatile compared to industry and market?
A214370 volatility
A214370 Average Weekly Movement15.5%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.5%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A214370 is more volatile than 90% of KR stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: A214370's weekly volatility has increased from 8% to 16% over the past year.

About the Company

2001157Yongji Chung

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR

Caregen Fundamentals Summary

How do Caregen's earnings and revenue compare to its market cap?
A214370 fundamental statistics
Market Cap₩1.03t
Earnings (TTM)₩25.32b
Revenue (TTM)₩59.09b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A214370 income statement (TTM)
Cost of Revenue₩13.64b
Gross Profit₩45.44b
Other Expenses₩20.13b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)2.58k
Gross Margin76.91%
Net Profit Margin42.85%
Debt/Equity Ratio0.0%

How did A214370 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Caregen undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: A214370 (₩105200) is trading above our estimate of fair value (₩67577.42)

Significantly Below Fair Value: A214370 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: A214370 is poor value based on its PE Ratio (40.7x) compared to the KR Pharmaceuticals industry average (26x).

PE vs Market: A214370 is poor value based on its PE Ratio (40.7x) compared to the KR market (14.2x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A214370's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A214370 is overvalued based on its PB Ratio (4.9x) compared to the KR Pharmaceuticals industry average (1.7x).

Future Growth

How is Caregen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Caregen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Caregen performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A214370 has high quality earnings.

Growing Profit Margin: A214370's current net profit margins (42.8%) are lower than last year (52.2%).

Past Earnings Growth Analysis

Earnings Trend: A214370's earnings have grown by 17.9% per year over the past 5 years.

Accelerating Growth: A214370's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A214370 had negative earnings growth (-19.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15.5%).

Return on Equity

High ROE: A214370's Return on Equity (12%) is considered low.

Financial Health

How is Caregen's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A214370's short term assets (₩149.3B) exceed its short term liabilities (₩9.8B).

Long Term Liabilities: A214370's short term assets (₩149.3B) exceed its long term liabilities (₩7.1B).

Debt to Equity History and Analysis

Debt Level: A214370 is debt free.

Reducing Debt: A214370 has not had any debt for past 5 years.

Debt Coverage: A214370 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: A214370 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet


What is Caregen current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A214370's dividend (1.52%) is higher than the bottom 25% of dividend payers in the KR market (0.85%).

High Dividend: A214370's dividend (1.52%) is low compared to the top 25% of dividend payers in the KR market (2.75%).

Stability and Growth of Payments

Stable Dividend: A214370 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: A214370 has only been paying a dividend for 2 years, and since then payments have fallen.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (108.4%), A214370's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (33.7%), A214370's dividend payments are well covered by cash flows.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Yongji Chung (51 yo)

no data


Mr. Yongji Chung, Ph D., serves as the Chief Executive Officer and Chief Technology Officer at Caregen Co., Ltd.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Caregen Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: Caregen Co., Ltd.
  • Ticker: A214370
  • Exchange: KOSDAQ
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩1.032t
  • Shares outstanding: 9.81m
  • Website:

Number of Employees


  • Caregen Co., Ltd.
  • Caregen Building
  • 46-38, LS-ro 91beon-gil
  • Anyang-Si
  • Gyeonggi-do
  • 14119
  • South Korea


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/10 00:00
End of Day Share Price2022/05/10 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.